Substandard Thyroxin Drugs Raise Safety Concerns In Sri Lanka
This article was originally published in PharmAsia News
Executive Summary
Questions are being raised about transparency in Sri Lanka's handling of problem drugs in the wake of substandard thyroxin drugs reaching the market. Physicians are concerned the problems are not well-publicized or that substitute drugs can be questionable. Neither the thyroid pills behind the new concern nor their manufacturers were identified, although the drugs were said to have been imported by Sri Lanka's health system from India and the U.K., and that raw material had come from China and Germany. Some thyroxin has been withdrawn, others have been blacklisted, and the registration of others has been canceled. Physicians in private and state institutions have complained about the medicines. (Click here for more